Featured Research

from universities, journals, and other organizations

Artificial pancreas: The way of the future for treating type 1 diabetes

Date:
January 28, 2013
Source:
Institut de recherches cliniques de Montreal
Summary:
Researchers have conducted a trial comparing a dual-hormone artificial pancreas with conventional diabetes treatment using an insulin pump and showed improved glucose levels and lower risks of hypoglycemia. Their results can have a great impact on the treatment of type 1 diabetes by accelerating the development of the external artificial pancreas.

External artificial pancreas: continual glucose monitor (left), pump worn on the belt that injects insulin under the patient’s skin (right), and a controller (here, a handheld smart phone).
Credit: Image courtesy of Institut de recherches cliniques de Montreal

IRCM researchers, led by endocrinologist Dr. Rémi Rabasa-Lhoret, were the first to conduct a trial comparing a dual-hormone artificial pancreas with conventional diabetes treatment using an insulin pump and showed improved glucose levels and lower risks of hypoglycemia. Their results, published January 28 in the Canadian Medical Association Journal (CMAJ), can have a great impact on the treatment of type 1 diabetes by accelerating the development of the external artificial pancreas.

Related Articles


The artificial pancreas is an automated system that simulates the normal pancreas by continuously adapting insulin delivery based on changes in glucose levels. The dual-hormone artificial pancreas tested at the IRCM controls glucose levels by automatically delivering insulin and glucagon, if necessary, based on continuous glucose monitor (CGM) readings and guided by an advanced algorithm.

"We found that the artificial pancreas improved glucose control by 15 per cent and significantly reduced the risk of hypoglycemia as compared with conventional insulin pump therapy," explains engineer Ahmad Haidar, first author of the study and doctoral student in Dr. Rabasa-Lhoret's research unit at the IRCM and at the Department of Electrical and Computer Engineering at McGill University. "The artificial pancreas also resulted in an 8-fold reduction of the overall risk of hypoglycemia, and a 20-fold reduction of the risk of nocturnal hypoglycemia."

People living with type 1 diabetes must carefully manage their blood glucose levels to ensure they remain within a target range. Blood glucose control is the key to preventing serious long-term complications related to high glucose levels (such as blindness or kidney failure) and reduces the risk of hypoglycemia (dangerously low blood glucose that can lead to confusion, disorientation and, if severe, loss of consciousness).

"Approximately two-thirds of patients don't achieve their target range with current treatments," says Dr. Rabasa-Lhoret, Director of the Obesity, Metabolism and Diabetes research clinic at the IRCM. "The artificial pancreas could help them reach these targets and reduce the risk of hypoglycemia, which is feared by most patients and remains the most common adverse effect of insulin therapy. In fact, nocturnal hypoglycemia is the main barrier to reaching glycemic targets."

"Infusion pumps and glucose sensors are already commercially-available, but patients must frequently check the sensor and adjust the pump's output," says Mr. Haidar. "To liberate them from this sizable challenge, we needed to find a way for the sensor to talk to the pump directly. So we developed an intelligent dosing algorithm, which is the brain of the system. It can constantly recalculate insulin dosing based on changing glucose levels, in a similar way to the GPS system in a car, which recalculates directions according to traffic or an itinerary change."

The researchers' algorithm, which could eventually be integrated as software into a smart phone, receives data from the CGM, calculates the required insulin (and glucagon, if needed) and wirelessly controls the pump to automatically administer the proper doses without intervention by the patient.

"The system we tested more closely mimics a normal pancreas by secreting both insulin and glucagon," adds Dr. Laurent Legault, peadiatric endocrinologist and outgoing Director of the Insulin Pump Centre at the Montreal Children's Hospital, and co-author of the study. "While insulin lowers blood glucose levels, glucagon has the opposite effect and raises glucose levels. Glucagon can protect against hypoglycemia if a patient with diabetes miscalculates the necessary insulin dose."

"Our work is exciting because the artificial pancreas has the potential to substantially improve the management of diabetes and reduce daily frustrations for patients," concludes Dr. Rabasa-Lhoret. "We are pursuing our clinical trials to test the system for longer periods and with different age groups. It will then probably be introduced gradually to clinical practice, using insulin alone, with early generations focusing on overnight glucose controls."

This study was conducted with 15 adult patients with type 1 diabetes, who had been using an insulin pump for at least three months. Patients were admitted twice to the IRCM's clinical research facility and received, in random order, both treatments: the dual-hormone artificial pancreas and the conventional insulin pump therapy. During each 15-hour visit, their blood glucose levels were monitored as they exercised on a stationary bike, received an evening meal and a bedtime snack, and slept at the facility overnight.

Dr. Rabasa-Lhoret's research is funded by Diabetes Québec, the Canadian Diabetes Association, and the IRCM's J.A. De Sève Chair in clinical research. IRCM collaborators who contributed to study include Maryse Dallaire, Ammar Alkhateeb, Adèle Coriati, Virginie Messier and Maude Millette.

About diabetes

Type-1 diabetes is a chronic, incurable disease that occurs when the body doesn't produce enough or any insulin, leading to an excess of sugar in the blood. It occurs most often in children, adolescents or young adults. People with type-1 diabetes depend on insulin to live, either through daily injections or with a pump. Diabetes is a major cause of vision loss, kidney and cardiovascular diseases.

According to the Canadian Diabetes Association, an estimated 285 million people worldwide are affected by diabetes, approximately 10 per cent of which have type 1 diabetes. With a further 7 million people developing diabetes each year, this number is expected to hit 438 million by 2030, making it a global epidemic. 


Story Source:

The above story is based on materials provided by Institut de recherches cliniques de Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ahmad Haidar, Laurent Legault, Maryse Dallaire, Ammar Alkhateeb, Adèle Coriati, Virginie Messier, Peiyao Cheng, Maude Millette, Benoit Boulet, Chiu-Ching Huang, Rémi Rabasa-Lhoret. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. Canadian Medical Association Journal, 2013 DOI: 10.1503/cmaj.121265

Cite This Page:

Institut de recherches cliniques de Montreal. "Artificial pancreas: The way of the future for treating type 1 diabetes." ScienceDaily. ScienceDaily, 28 January 2013. <www.sciencedaily.com/releases/2013/01/130128151928.htm>.
Institut de recherches cliniques de Montreal. (2013, January 28). Artificial pancreas: The way of the future for treating type 1 diabetes. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2013/01/130128151928.htm
Institut de recherches cliniques de Montreal. "Artificial pancreas: The way of the future for treating type 1 diabetes." ScienceDaily. www.sciencedaily.com/releases/2013/01/130128151928.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) — It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) — More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) — In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
The Best Protein-Filled Foods to Energize You for the New Year

The Best Protein-Filled Foods to Energize You for the New Year

Buzz60 (Dec. 19, 2014) — The new year is coming and nothing will energize you more for 2015 than protein-filled foods. Fitness and nutrition expert John Basedow (@JohnBasedow) gives his favorite high protein foods that will help you build muscle, lose fat and have endless energy. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins